Navigation Links
CardioDynamics Reports Second Fiscal Quarter 2009 Results
Date:7/9/2009

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) Impedance Cardiography (ICG) technology, today reported financial results for fiscal second quarter 2009. Highlights include 11% sequential revenue increase over Q1 2009 and 8% sensor growth compared with Q2 2008, the third consecutive quarter of year over year sensor growth.

Sales Highlights of Second Quarter 2009 Compared with Second Quarter 2008

  • Over 9,000 ICG monitors and modules sold to date, up 10% from 8,200 one year ago
  • ICG device sales totaled 169 units, including 129 stand alone ICG monitors, 94 of which were BioZ Dx systems, 10 BioZ monitors, and 25 Medis ICG monitors
  • ICG sensor revenue increased 8% to $1.9 million, comprising 33% of total sales compared with $1.7 million and 28% of revenue in Q2 2008
  • Field sales headcount totaled 69 associates, up from 67 one year ago

Key Financial Results of Second Quarter 2009 Compared with Second Quarter 2008

  • Operating cash use was $340,000, an improvement of $150,000 or 31%, from $490,000
  • Cash, cash equivalents and short-term investments at May 31, 2009, of $4.2 million
  • Operating loss was $1.1 million, which included $162,000 of non-cash charges for depreciation, amortization and equity compensation and $250,000 of merger transaction related expenses

Second Quarter 2009 Operating Results Discussion

The Company reported net sales of $5.7 million, a 9% decrease from second fiscal quarter 2008, but an 11% sequential increase over first fiscal quarter 2009. Year over year ICG sales decline was driven by 22% lower BioZ sales, partially offset by 8% growth in recurring sensor revenue. Sensor revenue grew 11% sequentially from first quarter 2009 to $1.9 million, recording the third consecutive quarter of sensor growth, averaging 10% growth over the three quarters. Gross margin as a percentage of sales decreased from 71% to 67% in the second quarter of 2009, largely due to a $3,000, or 10% decline in the average BioZ unit sales price in the direct domestic market resulting from a discount sales promotion offered during the second quarter. Operating expenses were essentially unchanged at $4.9 million compared with second quarter 2008. The second quarter of 2009 included approximately $250,000 of merger transaction-related expenses. Operating cash use was $340,000, an improvement of 31%, or $150,000, from $490,000 in the same quarter of 2008.

CEO Comments and Outlook

Michael K. Perry, Chief Executive Officer of CardioDynamics, stated, "We navigated through a tough quarter relatively well and were pleased with the third consecutive quarter of sensor revenue growth and 11% sequential revenue growth for the business. Economic conditions continue to put pressure on capital equipment spending in healthcare and this has affected demand for our BioZ systems. We are excited to join SonoSite, an industry leader in point of care medicine who shares our vision of creating non-invasive technologies that improve outcomes and reduce the cost of patient care. Being part of a larger company platform will provide additional resources that should enable accelerated growth for ICG technology in the years ahead."

Conference Call Information

Due to the merger with SonoSite which was announced on June 9, 2009, there will not be a quarterly financial conference call. The transaction is subject to shareholder approval and customary closing conditions and is anticipated to close during the third quarter of calendar 2009.

About CardioDynamics

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called impedance cardiography (ICG). The Company develops, manufactures and markets noninvasive ICG products and medical device electrodes. The Company's ICG Systems are being used by physicians around the world to help battle the number one killer of men and women--cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems and Mindray. For additional information, please refer to the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement

Except for historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which is necessarily subject to uncertainties and risks including the Company's primary dependence on the BioZ product line, and various uncertainties characteristic of early stage companies, as well as other risks detailed in the Company's filings with the SEC, including its 2008 Form 10-K. The Company does not undertake to update the disclosures contained in this press release.

                      CardioDynamics International Corporation
                   In thousands, except per share data (unaudited)

    Selected Consolidated
     Operational Results               Three Months Ended  Six Months Ended
                                              May 31,          May 31,
                                           2009    2008     2009     2008
    Net sales                            $5,652  $6,180  $10,724  $11,942
    Cost of sales                         1,885   1,772    3,240    3,547
    Gross margin                          3,767   4,408    7,484    8,395
    Research and development                370     370      765      684
    Selling and marketing                 3,725   3,721    7,295    7,443
    General and administrative              816     761    1,589    1,532
    Amortization of intangible assets         5      32       31       64
    Loss from operations                 (1,149)   (476)  (2,196)  (1,328)
    Other expense, net                     (277)   (192)    (502)    (358)
    Loss before income taxes and
     minority interest                   (1,426)   (668)  (2,698)  (1,686)
    Minority interest in income of
     subsidiary                             (19)    (11)     (68)    (145)
    Income tax provision                    (41)    (53)    (180)    (516)
    Income from discontinued operations       -       -        -      127
    Net loss                            $(1,486)  $(732) $(2,946) $(2,220)
    Net loss per common share:
      Basic and diluted                  $(0.20) $(0.10)  $(0.40)  $(0.31)
    Weighted-average shares used in per
     share calculation:
      Basic and diluted                   7,395   7,193    7,345    7,150

    Selected Consolidated Balance Sheet Data
                                                   May 31,       November 30,
                                                    2009             2008
    Cash and cash equivalents                      $4,187           $6,306
    Accounts receivable, net                        3,582            3,918
    Inventory, net                                  1,352            1,490
    Total current assets                            9,445           12,138
    Long-term assets                                3,583            3,428
    Total assets                                   13,028           15,566
    Total current liabilities                       3,912            4,499
    Long-term liabilities                           4,798            4,504
    Total liabilities                               8,710            9,003
    Minority interest                                 510              472
    Shareholders' equity                            3,808            6,091


'/>"/>
SOURCE CardioDynamics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CardioDynamics Announces Third Quarter 2007 Conference Call and Webcast
2. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
3. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
4. CardioDynamics Board of Directors Proposes Reverse Split 1:7 of Companys Shares
5. CardioDynamics Reports 22% Revenue Growth in First Quarter 2008
6. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
7. CardioDynamics Announces Second Quarter 2008 Conference Call and Webcast
8. CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008
9. CardioDynamics Announces Investors Retain $5.25 Million 8% Convertible Debt Securities
10. CardioDynamics Reports Eighth Consecutive Quarterly Revenue Increase Over Prior Year and 12% Revenue Growth in 2008
11. CardioDynamics Reports First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Georgia (PRWEB) , ... May 26, 2016 , ... ... certificate in intellectual property (IP) to its specialty academic programs. , Answering to ... the college’s existing certificate programs in health law, and environmental and land use ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will present ... Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. ... Retina Group of New York , is a Board Certified ophthalmologist who completed ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
(Date:5/26/2016)... ... 26, 2016 , ... Nike Yoga Camps at East West ... arts & crafts, discussions, and games all geared towards enhancing your child’s physical ... backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga training. Nike ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... Inivata, a global clinical ... tumour DNA (ctDNA) analysis to improve personalised healthcare ... Clive Morris as Chief Medical Officer. ... development programme, scientific collaborations, and through to commercialisation ... in clinical outcomes for patients. Clive ...
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
Breaking Medicine Technology: